Breaking Finance News

Patheon (NYSE:PTHN) has been downgraded from Overweight to Neutral in a statement by JP Morgan earlier today.

JP Morgan has downgraded Patheon (NYSE:PTHN) from Overweight to Neutral in a statement released on 6/8/2017.

Boasting a price of $34.75, Patheon (NYSE:PTHN) traded 0.00% even on the day. With the last stock price close down 0.00% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. PTHN has recorded a 50-day average of $34.98 and a two hundred day average of $34.98. Trade Volume was up over the average, with 229,751 shares of PTHN changing hands over the typical 0

Recent Performance Chart

Patheon (NYSE:PTHN)

Patheon has PE ratio of 44.85 with a one year low of $24.45 and a one year high of $35.02 and has a market capitalization of $0.

General Company Details For Patheon (NYSE:PTHN)

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.